SynthesisFrontiers in oncology2021

Comparison of the Efficacy and Safety of PARP Inhibitors as a Monotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis.

Hongmei Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.